

# Marta Pratcorona

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/658148/publications.pdf>

Version: 2024-02-01

198  
papers

15,395  
citations

94433

37  
h-index

18647

119  
g-index

201  
all docs

201  
docs citations

201  
times ranked

12925  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2022, 36, 90-99.	7.2	42
2	Prognostic impact of <i>DNMT3A</i> mutation in acute myeloid leukemia with mutated <i>NPM1</i> . <i>Blood Advances</i> , 2022, 6, 882-890.	5.2	15
3	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2022, 63, 538-550.	1.3	8
4	Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 43.e1-43.e5.	1.2	10
5	A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. <i>Biomaterials</i> , 2022, 280, 121258.	11.4	12
6	Follow-up of patients with R/R FLT3-mutation positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. <i>Blood</i> , 2022, 139, 3366-3375.	1.4	55
7	Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery. <i>Journal of Controlled Release</i> , 2022, 343, 277-287.	9.9	7
8	European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. <i>Blood Advances</i> , 2022, 6, 1193-1206.	5.2	26
9	Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. <i>Bone Marrow Transplantation</i> , 2022, 57, 896-902.	2.4	2
10	A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112940.	5.6	4
11	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	1.4	814
12	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. <i>Blood</i> , 2022, 140, 1345-1377.	1.4	805
13	Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future. <i>HemaSphere</i> , 2021, 5, e524.	2.7	23
14	Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes. <i>Leukemia Research</i> , 2021, 101, 106492.	0.8	0
15	Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1919-1928.	2.4	13
16	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.	7.2	51
17	Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 263-277.	1.9	5
18	Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2021, 56, 2432-2444.	2.4	33

#	ARTICLE	IF	CITATIONS
19	Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2021, 15, 326.	0.8	8
20	Current status of acute myeloid leukaemia in Spain: Results from a Delphi study on its epidemiology, disease management and unmet clinical needs. <i>Medicina Clínica</i> , 2021, 156, 573-574.	0.6	2
21	Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 614.e1-614.e8.	1.2	2
22	Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. <i>Journal of Controlled Release</i> , 2021, 335, 117-129.	9.9	11
23	The EHA Research Roadmap: Malignant Myeloid Diseases. <i>HemaSphere</i> , 2021, 5, e635.	2.7	2
24	The evolution of hematopoietic cells under cancer therapy. <i>Nature Communications</i> , 2021, 12, 4803.	12.8	28
25	Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2904-2910.	2.4	7
26	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 642-649.	1.2	65
27	Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study. <i>Blood</i> , 2021, 138, 3438-3438.	1.4	0
28	Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 4041-4041.	1.4	2
29	Midostaurin in Patients (Pts) with Newly Diagnosed FLT3-Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial. <i>Blood</i> , 2021, 138, 1303-1303.	1.4	1
30	Outcome of Human Umbilical Cord Blood Stem Cell Transplantation (CBT) for Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Versus Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2021, 138, 3964-3964.	1.4	0
31	A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. <i>Haematologica</i> , 2020, 105, 741-753.	3.5	36
32	Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. <i>Bone Marrow Transplantation</i> , 2020, 55, 641-648.	2.4	58
33	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	2.4	39
34	When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine). <i>Annals of Hematology</i> , 2020, 99, 157-165.	1.8	7
35	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	5.2	34
36	Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers – On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2098-2104.	2.0	9

#	ARTICLE	IF	CITATIONS
37	Feasibility of thiotepea addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1823-1832.	1.3	1
38	Impact of detectable measurable residual disease on umbilical cord blood transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1057-1065.	4.1	12
39	Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation â€“ a prospective, non-interventional study of the EBMT Transplant Complication Working Party. <i>Haematologica</i> , 2020, 105, 1977-1983.	3.5	5
40	Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002â€“2018 Empirical/Pre-emptive Approach. <i>Mycopathologia</i> , 2020, 185, 639-652.	3.1	0
41	Acute myeloid leukemia with <i>NPM1</i> mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. <i>British Journal of Haematology</i> , 2020, 191, 52-61.	2.5	28
42	UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy. <i>Leukemia</i> , 2020, 34, 2925-2933.	7.2	6
43	FcÎ³RIIb-BCR coligation inhibits BCR signaling in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 106, 306-309.	3.5	1
44	Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34); <i>DEK</i> â€“ <i>NUP214</i> shows a favourable outcome when performed in first complete remission. <i>British Journal of Haematology</i> , 2020, 189, 920-925.	2.5	16
45	Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT â€“ A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party. <i>Frontiers in Immunology</i> , 2020, 11, 586.	4.8	10
46	Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols. <i>European Journal of Haematology</i> , 2020, 105, 138-147.	2.2	12
47	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	1.4	127
48	Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment. <i>Frontiers in Pediatrics</i> , 2020, 8, 614521.	1.9	3
49	Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project). <i>Blood</i> , 2020, 136, 32-33.	1.4	0
50	Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection. <i>Blood</i> , 2020, 136, 22-23.	1.4	2
51	Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival. <i>Blood</i> , 2020, 136, 13-14.	1.4	0
52	The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality. <i>Blood</i> , 2020, 136, 14-15.	1.4	0
53	Management of Secondary Prevention in Venous Thromboembolism: Use of Reduced Doses of Rivaroxaban and Apixaban in Extended Therapy. <i>Blood</i> , 2020, 136, 16-17.	1.4	0
54	CAR-T Cells with High CAR Expression Intensity Have Improved <i>In Vitro</i> and <i>In Vivo</i> Anti-Lymphoma Effect without Functional Exhaustion. <i>Blood</i> , 2020, 136, 34-34.	1.4	0

#	ARTICLE	IF	CITATIONS
55	A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 288-296.	3.5	36
56	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 85, 106197.	0.8	16
57	Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas. <i>International Journal of Hematology</i> , 2019, 110, 406-410.	1.6	4
58	Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 815-819.	2.8	6
59	Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus. <i>Annals of Hematology</i> , 2019, 98, 2467-2483.	1.8	9
60	Stem cell transplantation for congenital dyserythropoietic anemia: an analysis from the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2019, 104, e335-e339.	3.5	14
61	Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. <i>Haematologica</i> , 2019, 104, 929-936.	3.5	23
62	GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. <i>Lancet Haematology</i> , 2019, 6, e89-e99.	4.6	47
63	Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients. <i>European Journal of Haematology</i> , 2019, 103, 208-214.	2.2	9
64	A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 2404-2414.	1.3	15
65	Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 683-694.	1.9	5
66	The Landscape of KMT2A-PTD AML: Concurrent Mutations, Gene Expression Signatures, and Clinical Outcome. <i>HemaSphere</i> , 2019, 3, e181.	2.7	14
67	The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma. <i>Oncolmmunology</i> , 2019, 8, e1546543.	4.6	5
68	Adquisición de la inv(16)(p13q22) en un caso de crisis blástica de leucemia mieloide crónica en tratamiento con imatinib. <i>Medicina Clínica</i> , 2019, 152, 419-420.	0.6	0
69	Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1022-1030.	2.0	11
70	Effectiveness and Safety of Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Patients with Active Cancer Therapy and Non Valvular Atrial Fibrillation. <i>Blood</i> , 2019, 134, 3661-3661.	1.4	2
71	Anticoagulation Challenges in Hematogeriatrics: Effectiveness and Safety of Direct Oral Anticoagulants Vs Vitamin k Antagonist in Elderly with Atrial Fibrillation. <i>Blood</i> , 2019, 134, 1162-1162.	1.4	0
72	Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. <i>British Journal of Haematology</i> , 2018, 181, 86-96.	2.5	23

#	ARTICLE	IF	CITATIONS
73	A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2394-2404.	1.3	16
74	Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2018, 53, 617-624.	2.4	45
75	Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival. <i>Leukemia and Lymphoma</i> , 2018, 59, 2383-2393.	1.3	1
76	CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. <i>Leukemia</i> , 2018, 32, 1168-1179.	7.2	133
77	Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. <i>Medical Oncology</i> , 2018, 35, 79.	2.5	15
78	Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. <i>Experimental Hematology</i> , 2018, 62, 24-32.	0.4	15
79	Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 55-63.	2.0	33
80	Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. <i>Cancers</i> , 2018, 10, 436.	3.7	8
81	Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. <i>Journal of Hematology and Oncology</i> , 2018, 11, 110.	17.0	41
82	Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis. <i>Bone Marrow Transplantation</i> , 2018, 53, 1478-1482.	2.4	7
83	Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 737-742.	0.4	1
84	Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2018, 101, 407-414.	2.2	7
85	CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis. <i>PLoS ONE</i> , 2018, 13, e0198789.	2.5	10
86	Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort. <i>Blood</i> , 2018, 132, 2736-2736.	1.4	44
87	FLT3 Inhibitor Treatment Increases FLT3 Expression That Exposes FLT3-ITD+ AML Blasts to Elimination By FLT3 CAR-T Cells. <i>Blood</i> , 2018, 132, 903-903.	1.4	7
88	Feasibility of the AML profiler (Skyline Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach. <i>Hematological Oncology</i> , 2017, 35, 778-788.	1.7	3
89	Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases. <i>Annals of Hematology</i> , 2017, 96, 787-796.	1.8	3
90	A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1177-1185.	2.0	22

#	ARTICLE	IF	CITATIONS
91	Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. <i>Haematologica</i> , 2017, 102, 1099-1104.	3.5	81
92	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 454-464.	27.0	1,628
93	Fc $\gamma$ RIIb expression in early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2642-2648.	1.3	7
94	Do Patients and Physicians Agree When They Assess Quality of Life?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1005-1010.	2.0	12
95	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 424-447.	1.4	4,375
96	Dendritic cells combined with tumor cells and $\alpha$ -galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma. <i>Journal of Translational Medicine</i> , 2017, 15, 115.	4.4	16
97	Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 491-497.	2.0	37
98	Haploidentical transplant in patients with myelodysplastic syndrome. <i>Blood Advances</i> , 2017, 1, 1876-1883.	5.2	28
99	<i>NEDD9</i> , an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients. <i>Oncotarget</i> , 2017, 8, 76003-76014.	1.8	5
100	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Oncotarget</i> , 2016, 7, 43027-43038.	1.8	40
101	Cord Blood Units with High CD3 + Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cell Depleted Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1073-1079.	2.0	11
102	Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. <i>Blood</i> , 2016, 128, e1-e9.	1.4	49
103	Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. <i>Journal of Hematology and Oncology</i> , 2016, 9, 118.	17.0	50
104	Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. <i>Blood</i> , 2016, 128, 1979-1986.	1.4	66
105	Total body-surface area as a new prognostic variable in mycosis fungoides and S $\alpha$ zary syndrome. <i>Leukemia and Lymphoma</i> , 2016, 57, 1060-1066.	1.3	9
106	Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. <i>European Journal of Haematology</i> , 2016, 96, 128-135.	2.2	19
107	Donor Lymphocyte Infusions for Haematological Malignancy Relapse. <i>Blood</i> , 2016, 128, 5775-5775.	1.4	0
108	Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 5281-5281.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. <i>Cancer Cell International</i> , 2015, 15, 122.	4.1	4
110	Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. <i>Cancer</i> , 2015, 121, 3809-3817.	4.1	43
111	CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e183-e185.	3.5	20
112	Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood—a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Hematology and Oncology</i> , 2015, 8, 107.	17.0	35
113	Few and Nonsevere Adverse Infusion Events Using an Automated Method for Diluting and Washing before Unrelated Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 682-687.	2.0	7
114	Complex Measurements May Be Required to Establish the Prognostic Impact of Immunophenotypic Markers in AML. <i>American Journal of Clinical Pathology</i> , 2015, 144, 484-492.	0.7	13
115	Post-Thaw Viable CD45 + Cells and Clonogenic Efficiency are Associated with Better Engraftment and Outcomes after Single Cord Blood Transplantation in Adult Patients with Malignant Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2167-2172.	2.0	17
116	Exploring the Expression Profile of Long Non-Coding RNA (lncRNA) in Different Acute Myeloid Leukemia (AML) Subtypes: t(8;16)(p11;p13)/MYST3-Crebbp AML Harbors a Distinctive Lncrna Signature. <i>Blood</i> , 2015, 126, 1397-1397.	1.4	2
117	Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH). <i>Blood</i> , 2015, 126, 4399-4399.	1.4	3
118	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (mut): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]). <i>Blood</i> , 2015, 126, 6-6.	1.4	104
119	PET/CT Assessment of Follicular Lymphoma and High Grade B Cell Lymphoma - Good Correlation with Clinical and Histological Features at Diagnosis. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 325-330.	1.4	30
120	The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. <i>Oncotarget</i> , 2015, 6, 31613-31627.	1.8	78
121	A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2553-2553.	1.4	0
122	Feasibility and Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in High-Risk AML: Real-Life Perspective from a Single Institution. <i>Blood</i> , 2015, 126, 4395-4395.	1.4	0
123	The Risk of Sinusoidal Obstruction Syndrome (SOS) in Allogeneic Hematopoietic Stem Cell Transplantation after Prior Gemtuzumab Ozogamicin Treatment: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2015, 126, 3110-3110.	1.4	0
124	High Correlation Clinical Responses to 1st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test. <i>Blood</i> , 2015, 126, 4837-4837.	1.4	0
125	Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Mediators of Inflammation</i> , 2014, 2014, 1-7.	3.0	16
126	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. <i>Blood</i> , 2014, 124, 1062-1069.	1.4	340



#	ARTICLE	IF	CITATIONS
127	Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1841-1846.	2.0	53
128	Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 305-318.	0.4	30
129	Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 66-72.	2.0	41
130	Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. <i>Haematologica</i> , 2014, 99, 1582-1590.	3.5	36
131	Results of the "Evaluation of NGS in AML-Diagnostics (ELAN) Study" an Inter-Laboratory Comparison Performed in 10 European Laboratories. <i>Blood</i> , 2014, 124, 2374-2374.	1.4	1
132	Matching of MHC Class I Chain-Related Genes a and B Is Associated with Reduced Incidence of Severe Acute Graft-Versus-Host Disease after Unrelated Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 664-664.	1.4	3
133	Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group. <i>Blood</i> , 2014, 124, 3798-3798.	1.4	0
134	R.I.S.C.L: A Holistic Molecular Diagnostic Tool for Myeloid Malignancies. <i>Blood</i> , 2014, 124, 2342-2342.	1.4	0
135	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. <i>Blood</i> , 2013, 121, 2734-2738.	1.4	246
136	The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycophenolate. <i>Haematologica</i> , 2013, 98, 526-532.	3.5	30
137	DNMT3A Mutation May Add Prognostic Value To Patients With Acute Myeloid Leukemia Of Intermediate Cytogenetic Risk Harboring a Favorable Genetic Profile Of NPM1, FLT3-ITD and CEBPA. <i>Blood</i> , 2013, 122, 1339-1339.	1.4	0
138	Long-Term Follow-Up Of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation For High Risk Follicular Lymphoma. <i>Blood</i> , 2013, 122, 5519-5519.	1.4	0
139	Pharmacological Profile Of Cytarabine and Idarubicin In Patient Samples (ex vivo) With Newly Diagnosed Acute Myeloid Leukemia Identifies Responders Vs Non Responders. <i>Blood</i> , 2013, 122, 3923-3923.	1.4	0
140	Personalizing Therapies With Ex Vivo Pharmacological Responses May Uncover The Differences Between IDA-DNR-MIT Among European AML Protocols. <i>Blood</i> , 2013, 122, 1294-1294.	1.4	0
141	Identification Of Patients At High Risk Of Chronic Graft-Versus-Host Disease: Gvhd Prophylaxis. <i>Blood</i> , 2013, 122, 4611-4611.	1.4	0
142	Treatment With G-CSF Reduces Acute Myeloid Leukemia (AML) Blasts Viability In Presence Of Bone Marrow Stroma. <i>Blood</i> , 2013, 122, 1422-1422.	1.4	0
143	Population Pharmacological Profiles Of AML Treatments In Patient Samples By Automated Flow Cytometry; A Bridge To Individualized Medicine. <i>Blood</i> , 2013, 122, 1347-1347.	1.4	0
144	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 579-590.	27.6	352

#	ARTICLE	IF	CITATIONS
145	Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. <i>Blood</i> , 2012, 119, 5824-5831.	1.4	221
146	Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. <i>Haematologica</i> , 2012, 97, 388-392.	3.5	143
147	WT1 Levels At Diagnosis and POST-Induction Provide Prognostic Information in Adult De Novo AML. Results From the Spanish Cetlam Group.. <i>Blood</i> , 2012, 120, 2524-2524.	1.4	0
148	Feasibility of the AMLprofiler <sup>®</sup> , <sup>®</sup> (Skyline array) in Patient Risk-Stratification in a Multicenter Trial. Comparison with the Standard Approach. <i>Blood</i> , 2012, 120, 4813-4813.	1.4	0
149	Multilineage Dysplasia Confers Poor Prognosis to Patients with De Novo Acute Myeloid Leukemia with Intermediate-Risk Cytogenetics and Wild-Type NPM1.. <i>Blood</i> , 2012, 120, 2551-2551.	1.4	0
150	Improved Response to 5-Azacytidine in Patients with Primary Compared to Secondary AML, Particularly If NPM1 Mutations Are Present., <i>Blood</i> , 2011, 118, 3562-3562.	1.4	0
151	The Combination of Siromilus Plus Tacrolimus (SiTac) Improves the Results of Cyclosporine Plus Mycophenolate Mofetil (CsAMMF) After Reduced Intensity Conditioning (RIC) Unrelated Donor Allogeneic Transplantation. <i>Blood</i> , 2011, 118, 890-890.	1.4	0
152	5-Azacytidine Before or After Stem Cell Transplantation in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2011, 118, 4267-4267.	1.4	0
153	WT1 Protein Expression in Myeloid Malignancies: An Immunohistochemical Study. <i>Blood</i> , 2011, 118, 4886-4886.	1.4	0
154	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010, 115, 453-474.	1.4	2,963
155	A Distinctive MicroRNA Signature Characterizes Acute Myeloid Leukemia with Translocation (8;16)(p11;p13) and MYST3-CREBBP Rearrangement. <i>Blood</i> , 2010, 116, 230-230.	1.4	1
156	Prognostic Value of Monosomal Karyotype in Patients with Primary Acute Myeloid Leukemia On Behalf of Spanish CETLAM Group.. <i>Blood</i> , 2009, 114, 1003-1003.	1.4	3
157	Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 2611-2611.	1.4	0
158	Reported Bone Pain in Cancer Patients Receiving Chemotherapy in Pegfilgrastim Clinical Trials: A Retrospective Analysis.. <i>Blood</i> , 2009, 114, 4561-4561.	1.4	0
159	A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. <i>BMC Cancer</i> , 2008, 8, 195.	2.6	46
160	Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 577-584.	1.6	213
161	Similar 5-Year Survival after Peripheral Blood Autotransplants (AutoPB) Versus HLA Matched Sibling Myeloablative Transplants (AlloBMT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).. <i>Blood</i> , 2008, 112, 2168-2168.	1.4	3
162	Similar Outcomes Using Myeloablative Versus Reduced Intensity and Non-Myeloablative Allogeneic Transplant Preparative Regimens for AML or MDS: From the Center for International Blood and Marrow Transplant Research. <i>Blood</i> , 2008, 112, 348-348.	1.4	9

#	ARTICLE	IF	CITATIONS
163	Treatment of Chronic Myeloid Leukemia with Imatinib. A Single Centre Experience. Blood, 2008, 112, 4289-4289.	1.4	0
164	Long Term Results of Fludarabine/Melphalan as Reduced Intensity Conditioning Regimen (RIC) for Transplantation in Mantle Cell Lymphoma (MCL): Age Matters. Blood, 2008, 112, 4388-4388.	1.4	0
165	Therapeutic Antimyeloma Effect of Dendritic-Tumor Cells Hybrids Transduced with Adenovirus Encoding CD40L.. Blood, 2008, 112, 1709-1709.	1.4	0
166	One Antigen HLA-Mismatched Related and 8/8 Allele Matched Unrelated Donors Are Associated with Similar Survival after Hematopoietic Cell Transplantation for Acute Leukemia.. Blood, 2008, 112, 965-965.	1.4	7
167	Targeting the Poor Mobilizing Population of Patients for An Autologous Transplantation Procedure: A Single Centre Experience. Blood, 2008, 112, 4136-4136.	1.4	0
168	Prevalence of EVI1 Overexpression and Its Impact on Diagnosis and Prognosis in Acute Myeloid Leukemia: A Study of 490 Patients from the Spanish Group of Myeloid Malignancies of the RTICC.. Blood, 2008, 112, 1515-1515.	1.4	13
169	The Use of Tetradenoylphorbol Acetate Stimulated Peripheral Blood Cells for Interphase Fluorescence In-Situ Hybridization Analysis May Enhance Its Prognostic Value for Patients with Chronic Lymphocytic Leukemia. Blood, 2008, 112, 4152-4152.	1.4	0
170	Cyclosporine a and Mycophenolate Mofetil Vs Cyclosporine a and Methotrexate as Gvhd Prophylaxis in Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donor.. Blood, 2008, 112, 2229-2229.	1.4	0
171	Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Using Oral Fludarabine as Part of the Conditioning Regimen.. Blood, 2007, 110, 4925-4925.	1.4	0
172	Comparison of Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate in Reduced Intensity Conditioning HLA Sibling Allogeneic Stem Cell Transplantation. A Case-Match Single-Center Experience.. Blood, 2007, 110, 4994-4994.	1.4	0
173	The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 3014-3014.	1.4	0
174	Abnormal CD34 Positive Cells Are Present in NPM+ Acute Myeloid Leukemia (AML) Samples at Diagnosis.. Blood, 2007, 110, 4289-4289.	1.4	0
175	Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood, 2006, 108, 836-846.	1.4	337
176	Correlation between WT1 Levels and Chimeric Transcripts in Core Binding Factor AML: Discrepancies Are Not Uncommon AML1-ETO Leukemias.. Blood, 2006, 108, 2309-2309.	1.4	0
177	Study on the Efficacy and Safety of IGIV3I Grifols (Human Intravenous Immunoglobulin) in Patients Diagnosed with Chronic Immune Thrombocytopenic Purpura.. Blood, 2006, 108, 3956-3956.	1.4	1
178	Uniparental Disomy May Be Associated with NPM Mutations in AML with a Normal Karyotype.. Blood, 2006, 108, 2310-2310.	1.4	0
179	Long Remission Are Possible after Non Myeloablative Transplant in Patients with Follicular Non-Hodgkin's Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.. Blood, 2006, 108, 3024-3024.	1.4	0
180	Fludarabine and Busuphan (Flu-Bu) as Reduced Intensity-Conditioning (RIC) Regimen in HLA-Identical Sibling Allogeneic Hematopoietic Stem Transplantation (Allo-SCT) for Myeloid Malignancies. Results of a Prospective Multicenter Study.. Blood, 2006, 108, 5363-5363.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Reduced-Intensity Conditioning Allogeneic Blood Stem Cell Transplantation with Fludarabine and Oral Busulfan with or without Pharmacokinetically Targeted Busulfan Dosing in Patients with Myeloid Leukemia Ineligible for Conventional Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 437-447.	2.0	26
182	Impact of Dendritic Cell CD16+ Recovery on Outcome after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2005, 106, 1409-1409.	1.4	0
183	Cisplatin-Based Protocols as Salvage Therapy for Relapsed or Refractory Hodgkin's Lymphoma Patients. <i>Blood</i> , 2005, 106, 2676-2676.	1.4	1
184	Rituximab-Mediated Antibody-Dependent Cellular Cytotoxicity Is Enhanced by Interleukin-15 or CpG Oligodeoxynucleotides. <i>Blood</i> , 2005, 106, 2440-2440.	1.4	0
185	Pegfilgrastim Supports Delivery of CHOP-R Chemotherapy Administered Every 14 Days: A Randomised Phase II Study. <i>Blood</i> , 2004, 104, 3311-3311.	1.4	8
186	A Multicentre, Double-Blind, Randomized, Phase 2 Trial Comparing Pegfilgrastim with Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML). <i>Blood</i> , 2004, 104, 866-866.	1.4	4
187	Influence of the Intensity of the Conditioning Regimen on the Characteristics of Acute and Chronic Graft Versus Host Disease after Allogeneic Transplantation. <i>Blood</i> , 2004, 104, 5157-5157.	1.4	0
188	Minimal Residual Disease (MRD) Analysis in Acute Myeloid Leukemia (AML) with Favorable Cytogenetics [t(8;21) and inv(16)] by Real Time PCR(RT-PCR) and Flow Cytometry (FC). <i>Blood</i> , 2004, 104, 2989-2989.	1.4	0
189	Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. <i>British Journal of Haematology</i> , 2001, 114, 544-550.	2.5	23
190	Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyt. <i>British Journal of Haematology</i> , 2001, 114, 931-936.	2.5	60
191	Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. <i>British Journal of Haematology</i> , 2001, 115, 653-659.	2.5	102
192	No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. <i>British Journal of Haematology</i> , 2000, 110, 308-314.	2.5	64
193	Intensified Prophylaxis of Febrile Neutropenia with Ofloxacin Plus Rifampin During Severe Short-Duration Neutropenia in Patients with Lymphoma. <i>Leukemia and Lymphoma</i> , 1999, 34, 585-589.	1.3	8
194	Autologous or Allogeneic Stem Cell Transplantation in Advanced Low-Grade Lymphomas?. <i>Blood</i> , 1998, 91, 4810-4811.	1.4	0
195	Successful autografting in chronic myelogenous leukaemia using Philadelphia negative blood progenitor cells mobilized with rHuG-CSF alone in a patient responding to alpha-interferon. <i>British Journal of Haematology</i> , 1997, 96, 421-423.	2.5	8
196	The value of detecting surface and cytoplasmic antigens in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1992, 81, 178-183.	2.5	33
197	Specific cutaneous involvement in Hodgkin's disease. <i>Hematological Oncology</i> , 1992, 10, 75-79.	1.7	39
198	Mitoxantrone and intermediate-dose cytosine arabinoside for poor-risk acute leukemias: Response to treatment and factors influencing outcome. <i>Hematological Oncology</i> , 1992, 10, 301-309.	1.7	7